




This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: <https://creativecommons.org/licenses/by/4.0/> which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited. © The Author(s) 2023

Pakistan Journal of Nuclear Medicine is the official journal of Pakistan Society of Nuclear Medicine

Incidental ^{18}F -fluorodeoxyglucose uptake in respiratory muscles in a patient with Hodgkin lymphoma

Yassir Benameur^{1*} , Adnane Hammani², Salah Nabih Oueriagli¹, El Mehdi Mahtat², Omar Ait Sahel¹, Kamal Doghmi², Abderrahim Doudouh¹

Received: 24 December 2021

Revised:

Accepted: 19 April 2022

Correspondence to: Yassir Benameur

Department of Nuclear Medicine, Mohammed V Military Teaching Hospital, Rabat, Morocco.

Email: benameur.yassir@gmail.com

Full list of author information is available at the end of the article.

A 60-year-old male patient diagnosed with Hodgkin lymphoma 2 years ago, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine protocol with complete metabolic response on fluorodeoxyglucose Positron Emission Tomography and Computed Tomography. (FDG-PET/CT) at the end of chemotherapy.

^{18}F -FDG PET/CT was performed for suspicion of relapse and showed incidental marked ^{18}F -FDG uptake on the diaphragm, in the intercostal, and in the scalene muscles, representing excessive strain and work of virtually all respiratory muscles. The patient was not diabetic; he was fasting and had no history of insulin injection before the exam. No strenuous exercise was performed in the few days before undergoing PET/CT. Clinically, he presented with a progressive shortness of breath and paroxysmal nonproductive cough and had a slight inspiratory pull, especially visible in the supraclavicular area.

He was managed with bilateral pneumonia secondary to chemotherapy-induced immunosuppression.

Differential diagnosis were atypical pneumonia, disseminated Koch's disease, and progression of HL with lung involvement. High-resolution Chest CT showed extensive bilateral ground-glass opacifications with areas of alveolar infiltrates as well as some background reticulations (suggestive of fibrotic changes). Based on the clinical and chest CT findings, a diagnosis of probable pulmonary fibrosis secondary to Bleomycin was made.

Increased ^{18}F -FDG activity in skeletal muscle has been reported during excessive use of skeletal muscles, glucose metabolism is enhanced, leading to increased FDG uptake. Although malignant process has high affinity for ^{18}F -FDG, the physiological processes like talking, chewing and hyperventilation may lead to diffuse increased uptake in the involved group of muscles.

Incidental marked ^{18}F -FDG uptake in accessory muscles of respiration has been previously reported in the literature in patients with chronic obstructive pulmonary disease, Lin et al. [1] described a case of a patient with




Figure 1. FDG-PET/CT demonstrate hypermetabolic activity in accessory muscles of respiration, including the scalenes, intercostals, diaphragm and crura of the diaphragm.

a: Whole-body maximum-intensity projection images in the anterior, right and left views.

b, c, d: Fused coronal and transaxial FDG-PET/CT images.

history of chronic obstructive pulmonary disease associated with small-cell lung cancer, excessive metabolic activity in thoracic muscles has also been shown in radiation pneumonitis, as on the case reported by Bural et al. [2] in a patient treated for pharyngeal wall cancer and who developed radiation fibrosis. In Hodgkin lymphoma, chemotherapy and radiotherapy can cause long-term toxicities like pulmonary fibrosis, especially if bleomycin is a part of standard chemotherapy [3].

The lack of specificity of FDG uptake in skeletal muscle may cause misinterpretation of FDG-PET scans. The FDG uptake on skeletal muscle is probably one of the most important aspects that leads to pitfalls in the evaluation of F-18 FDG PET scans [4].

Benzodiazepines have been successfully used before PET/CT imaging to relieve anxiety in claustrophobic patients and to relax skeletal muscles [5]. The Society of Nuclear Medicine and Molecular Imaging suggests that the administration of Lorazepam or Diazepam before the injection of ¹⁸F-FDG may reduce uptake by skeletal muscle [6].

Author details

Yassir Benameur¹, Adnane Hammani², Salah Nabih Oueriagli¹, El Mehdi Mahtat², Omar Ait Sahel¹, Kamal Doghmi², Abderrahim Doudouh¹

1. Department of Nuclear Medicine, Mohammed V Military Teaching Hospital, Rabat, Morocco
2. Departments of Clinical Hematology, Mohammed V Military Teaching Hospital, Rabat, Morocco

References

1. Lin FI, Foster CC, Hagge RJ, Shelton DK. Extensive FDG uptake in accessory muscles of respiration in a patient with

shortness of breath. *Clin Nucl Med.* 2009;34(7):428–30. <https://doi.org/10.1097/RLU.0b013e3181a7d1a9>

2. Bural GG, Mavi A, Kumar R, Alavi A. FDG uptake in intercostal muscles is an indicator of severe respiratory disease. *Clin Nucl Med.* 2004;29(12):807–8. <https://doi.org/10.1097/00003072-200412000-00010>
3. Pepper NB, Oertel M, Kittel C, Kröger KJ, Elsayad K, Haverkamp U, et al. Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma. *Strahlenther Onkol.* 2021;197(1):56–62. <https://doi.org/10.1007/s00066-020-01682-0>
4. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. *Semin Nucl Med.* 2004;34(2):122–33. <https://doi.org/10.1053/j.semnuclmed.2003.12.003>
5. Surasi DS, Bhambhani P, Baldwin JA, Almodovar SE, O'Malley JP. ¹⁸F-FDG PET and PET/CT patient preparation: a review of the literature. *J Nucl Med Technol.* 2014;42(1):5–13. <https://doi.org/10.2967/jnmt.113.132621>
6. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. *J Nucl Med.* 2006;47(5):885–95. Erratum in: *J Nucl Med.* 2006;47(6):903.

Conflict of interest

The authors declare no conflict of interest.

Funding

The authors declared that this study received no financial support.

Consent to participate

Not Applicable.

Consent of ethics

Not Applicable.

Ethical approval

Not Applicable.